Læknablaðið - 15.02.2009, Qupperneq 54

VIÐ PARKINSONS SJÚKDÓMI
Einlyfjameðferð og viðbótarmeðferð
Áhrifaríkt
Einfalt
J^u^dl>«ck
*
A ^ ^ 1 mg á dag
Azilect
rasagílín
Einu sinni á dag
Heimildir
1. Parkinson Study Group. A Controlled Trial of Rasagiline in Early Parkinson Disease.TheTEMPO Study. Arch Neurol 2002; 59:1937-43
2. Rascol et al, for the LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor þuctuations (LARGO, Lasting effect in Adjunct therapy with
Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365:947-54
3. Parkinson Study Group.A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated PatientsWith Parkinson Disease and Motor Fluctuations.The PRESTO Study.Arch Neurol
2005;62:241-248
Sérlyfjatexti á bls. 161